Introduction: Addressing Cell Culture Demand, Fetal Bovine Serum Supply, and Biopharmaceutical Research Needs
For biopharmaceutical researchers, cell culture scientists, and veterinary diagnostic manufacturers, animal blood and components (plasma, serum, red blood cells, white blood cells, platelets, hemoglobin) are essential reagents for cell culture (fetal bovine serum, FBS), diagnostic assays (antibodies, antigens), vaccine production (viral growth media), and biomedical research (disease models, drug testing, toxicology). Fetal bovine serum (FBS) is the most widely used cell culture supplement (10–20% v/v) for mammalian cell growth (CHO, HEK293, Vero, MDCK, hybridomas). Other animal blood components (canine, feline, sheep, equine, camelid) are used for species-specific diagnostic reagents, veterinary vaccines, and comparative biology research. As biopharmaceutical production expands (mAbs, recombinant proteins, vaccines), cell culture demand grows (10–15% CAGR), and veterinary diagnostics market increases (pet humanization, livestock disease surveillance), demand for high-quality, consistent animal blood components is growing. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Animal Blood & Components – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Animal Blood & Components market, including market size, share, demand, industry development status, and forecasts for the next few years.
For biopharmaceutical procurement managers, cell culture scientists, and veterinary diagnostic directors, the core pain points include achieving consistent quality (sterility, endotoxin-free, mycoplasma-free, virus-free), supply chain security (FBS from BSE-free countries), and regulatory compliance (FDA, EMA, USDA, OIE). According to QYResearch, the global animal blood & components market was valued at US$ 1,638 million in 2025 and is projected to reach US$ 2,562 million by 2032, growing at a CAGR of 6.7% . In 2024, global production reached 1,867.09 kiloliters, with an average selling price of US$ 878 per liter.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/6097274/animal-blood—components
Market Definition and Core Capabilities
Animal blood is a fluid tissue composed of plasma and blood cells (red blood cells, white blood cells, platelets), performing transportation, regulation, and protection functions. Core components and capabilities:
- Plasma (55–60% of blood volume): Water (90–92%), proteins (albumin, globulins, fibrinogen), inorganic salts, nutrients, hormones, growth factors. Serum (plasma minus clotting factors) – most common cell culture supplement (FBS).
- Red Blood Cells (RBCs): Hemoglobin (oxygen carrier). Used for red blood cell concentrates, hemoglobin solutions, and red blood cell membranes (research).
- White Blood Cells (WBCs): Immune cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils). Used for immunological research, cytokine production, cell-based assays.
- Platelets: Thrombocytes. Used for platelet-rich plasma (PRP), wound healing research, coagulation studies.
- Animal Species: Bovine (cattle) – largest segment (80–85% of revenue). Canine (dogs) – veterinary diagnostics, research. Feline (cats) – veterinary diagnostics, research. Sheep – veterinary vaccines, research. Equine (horses) – veterinary diagnostics, antivenom production. Camelid (camels, llamas, alpacas) – nanobody production (single-domain antibodies, VHH). Others (porcine, rabbit, goat, chicken, rat, mouse).
Market Segmentation by Animal Species
- Bovine (Cattle) (80–85% of revenue, largest segment): Fetal bovine serum (FBS) – gold standard cell culture supplement (10–20% v/v). Newborn calf serum (NBCS), calf serum, adult bovine serum. Bovine blood components for biopharmaceutical research (mAb production, vaccine manufacturing). Sourced from BSE-free countries (US, Canada, Australia, New Zealand, Europe). Dominant in North America, Europe, Australia.
- Canine (Dogs) (5–10% of revenue, fastest-growing at 7–8% CAGR): Canine serum, plasma, red blood cells for veterinary diagnostics (heartworm, Lyme disease, ehrlichiosis, anaplasmosis), vaccine research (rabies, distemper, parvovirus), and comparative oncology. Growing demand for pet healthcare (pet humanization, veterinary diagnostics market $10B+).
- Feline (Cats) (3–5% of revenue): Feline serum, plasma for veterinary diagnostics (feline leukemia virus, feline immunodeficiency virus, feline coronavirus), vaccine research, and infectious disease studies.
- Sheep (2–3% of revenue): Sheep blood for vaccine production (foot-and-mouth disease, Q fever), complement fixation tests, and research (reproductive biology, immunology).
- Equine (Horses) (2–3% of revenue): Horse serum for antivenom production (snake bites), tetanus antitoxin, and veterinary diagnostics.
- Camelid (Camels, Llamas, Alpacas) (1–2% of revenue, fastest-growing at 8–9% CAGR): Camelid serum for nanobody production (single-domain antibodies, VHH). Nanobodies used for research (protein capture, immunology), diagnostics (ELISA, lateral flow), and therapeutics (cancer, autoimmune diseases). Growing demand for nanobody technology.
- Others (1–2% of revenue): Porcine (pigs), rabbit, goat, chicken, rat, mouse blood for research, diagnostics, vaccine production.
Market Segmentation by Application
- Medical Research (45–50% of revenue, largest segment): Cell culture (FBS for CHO, HEK293, Vero, MDCK, hybridomas). Biopharmaceutical production (mAbs, recombinant proteins, viral vectors, vaccines). Drug discovery (cell-based assays, toxicity testing). Gene therapy (AAV, lentivirus production). Stem cell research (iPSC, MSC). Tissue engineering.
- Scientific Research (25–30% of revenue): Immunology (antibody production, complement assays). Cancer research (cell lines, xenografts). Neuroscience (primary neurons). Infectious disease (virus propagation). Comparative biology (species differences). Veterinary research.
- Industrial Applications (10–15% of revenue): Diagnostic reagents (antibodies, antigens, controls). Vaccine production (viral growth media, cell culture). Quality control (sterility testing, endotoxin testing). Food safety (pathogen detection).
- Other (5–10% of revenue): Veterinary diagnostics (heartworm, Lyme disease, ehrlichiosis, anaplasmosis, FeLV, FIV, FIP). Animal nutrition (blood meal, plasma protein). Cosmetics (animal-derived ingredients).
Technical Challenges and Industry Innovation
The industry faces four critical hurdles. Fetal Bovine Serum (FBS) Supply & Ethics – FBS collected from pregnant cows (slaughterhouse byproduct). Supply constraints (BSE-free countries, seasonal). Ethical concerns (animal welfare). Alternatives: serum-free media, chemically defined media, recombinant albumin, plant-based hydrolysates. Viral & Mycoplasma Contamination – animal blood may contain adventitious agents (bovine viral diarrhea virus, BVDV; bovine parvovirus; mycoplasma). Testing (PCR, in vitro, in vivo) and inactivation (gamma irradiation, heat treatment) ensure safety. Batch-to-Batch Variability – animal blood components vary by donor (age, breed, health), collection (season, diet), and processing (centrifugation, filtration, pooling). Pooling (large batches) reduces variability. Regulatory Compliance – FDA (US), EMA (Europe), USDA (animal health), OIE (World Organisation for Animal Health). BSE/TSE (transmissible spongiform encephalopathy) risk mitigation (sourcing from BSE-free countries). Traceability (origin, processing, testing).
独家观察: FBS Dominates; Canine & Camelid Fastest-Growing Segments
An original observation from this analysis is the fetal bovine serum (FBS) dominance (80–85% share) for cell culture and biopharmaceutical research . FBS is gold standard supplement for mammalian cell culture (10–20% v/v). Growing demand for biopharmaceutical production (mAbs, recombinant proteins, viral vectors, vaccines) drives FBS market. FBS segment projected 85%+ of bovine blood revenue by 2030. Additionally, canine (dogs) and camelid (camels, llamas, alpacas) blood components are fastest-growing segments (7–9% CAGR) for veterinary diagnostics (pet humanization) and nanobody production (single-domain antibodies). Canine segment projected 10%+ of animal blood revenue by 2030 (vs. 5% in 2025). Camelid segment projected 3–5% of revenue by 2030 (nanobody market $500M+).
Strategic Outlook for Industry Stakeholders
For CEOs, product line managers, and biopharmaceutical investors, the animal blood & components market represents a steady-growth (6.7% CAGR), essential research reagent opportunity anchored by biopharmaceutical production, cell culture demand, and veterinary diagnostics. Key strategies include:
- Investment in fetal bovine serum (FBS) supply chain (BSE-free countries) for biopharmaceutical and cell culture research (largest segment).
- Development of canine and feline blood components for veterinary diagnostics (pet humanization, fastest-growing segments).
- Expansion into camelid blood components for nanobody production (single-domain antibodies, VHH) for research, diagnostics, therapeutics.
- Geographic expansion into Asia-Pacific (China, India, Southeast Asia) for biopharmaceutical production (mAbs, vaccines) and veterinary diagnostics growth.
Companies that successfully combine consistent quality, supply chain security, and regulatory compliance will capture share in a $2.56 billion market by 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
